The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Epidemiology, Risk factors, Prevention, and Health Services Research


Genitourinary Cancers

2009 Genitourinary Cancers Symposium

For a list of disclosures, please use the Disclosure links at the bottom of this page.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


Sort by: title abstract no. first author  |  Search Abstracts

ABSTRACT TITLE FIRST AUTHOR     ABSTRACT NO.
The PSA threshold for a prostate biopsy: Should it be lowered from 3.0 ng/ml to 2.0 ng/ml in a screening setting? (ERSPC Rotterdam).

M. J. Roobol

2

Feasibility and clinical utility of a TMPRSS2:ERG gene fusion urine test.

J. Groskopf

3

The natural history of metastatic progression in men with PSA-recurrent prostate cancer (PCa) after radical prostatectomy: 25-year follow-up.

E. S. Antonarakis

5

Influence of baseline subject characteristics on biopsy outcomes in the REDUCE (REduction by DUtasteride in prostate Cancer Events) trial.

G. L. Andriole

8

Implication of fluctuating prostate-specific antigen for risk of prostate cancer.

G. Taverna

9

Plasmatic levels of c-erbB2 soluble receptor (SR-HER-2/neu) and prostate cancer diagnosis.

M. Tobias-Machado

10

The value of PSA and other risk factors in determining the future risk of prostate cancer: Data from the Rotterdam section of the European randomized study of screening for prostate cancer.

M. J. Roobol

13

No evidence for a treatment bias in the European Randomized Study of Screening for Prostate Cancer (ERSPC).

T. Wolters

15

Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate-specific antigen level.

S. Loeb

16

Survival following radiation and androgen suppresion therapy for prostate cancer in healthy older men: Implications for screening recommendations.

P. L. Nguyen

17

Effect of testosterone and sex hormone levels on serum PSA concentration in the PLCO Cancer Screening Trial.

A. Black

18

Screening for prostate cancer—How many biopsies are needed?

F. H. Schröder

19

Correlation of BRCA2 mutation and prostate cancer phenotype.

D. J. Gallagher

20

Independent replication of a four kallikrein panel to detect prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands.

A. Vickers

21

Hormone therapy for prostate cancer induces the metabolic syndrome: Is it preventable?

J. P. Nobes

22

Early mortality after treatment for localized prostate cancer.

C. A. Reddy

23

Race differences with respect to treatment (tx) among SEER/Medicare patients (pts) with stage IV prostate cancer (PCa).

E. Onukwugha

24

Global quality of life (QOL) in prostate cancer survivors: Quantifying the impact of treatment-related dysfunction.

R. C. Chen

25

Statin use and death from prostate cancer: A state-wide, population-based study.

S. Marcella

26

Genetic variants associated with familial prostate cancer may be informative of time to prostate cancer diagnosis in African American men.

V. N. Giri

27

Comparison of the costs of robotic, laparoscopic and open radical prostatectomy.

A. Gupta

28

Cost-utility analysis of radiation techniques for low-risk, clinically localized prostate cancer.

J. H. Hayes

29

Detecting disparities in long-term prostate cancer (PCa) survival with dependent censoring.

J. M. Clement

30

Screening for prostate cancer: Should we perform an extended number of biopsies in men with large prostate volumes?

P. J. van Leeuwen

32

Population dependency of neural networks.

T. Köpke

33

Exploring the interaction between androgen suppression therapy and radiation therapy and their effect on the rate of hip fractures in patients with prostate cancer.

S. R. Alanee

34

Validating the Partin Tables using the NCI SEER database.

J. B. Yu

35

Optimizing prostate cancer screening policies using partially observable Markov decision processes.

B. A. Inman

37

Correlation of tumor percentage involvement and PSA recurrence in men with smaller prostates.

M. A. Uhlman

39

Incidence of higher risk prostate cancer and PSA recurrence in obese African Americans in the modern era.

A. Caire

40

Race and time from diagnosis to radical prostatectomy: Does equal-access mean equal Timely access to the operating room? Results from the SEARCH Database.

L. L. Bañez

44

Outpatient prostatectomy: Too much too soon or just what the patient ordered?

A. D. Martin

45

Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: Results from the SEARCH Database.

D. M. Moreira

48

Insignificant prostate cancer: The Duke experience.

D. A. Stackhouse

50

Prostate cancer in men over 70 in the modern era.

B. D. Lack

51

Small cell carcinoma of the prostate: Patient and tumor characteristics, natural history, and outcome.

J. Wang

52

Does written information decrease the anxiety of patients scheduled for prostate biopsy?

B. Tombal

59

Trends in health disparities in staging of prostate cancer patients.

C. D. Mullins

61

Do individual differences in cognition affect treatment preferences for early-stage prostate cancer?

S. E. Fogh

62

Effect of cancer symptoms on quality of life in genitourinary cancer: A multivariate analysis.

D. Gupta

67

Does anxiety about prostate cancer lead to increased lifestyle modifications including complementary and alternative medicine (CAM) among patients with biochemical recurrence?

R. T. Lee

70

Patient navigation in Chicago: Targeting barriers to follow-up care after an abnormal screening test for prostate cancer.

N. Nonzee

71

The impact of specialist visits on treatment (tx) among elderly patients (pts) with stage IV prostate cancer (PCa): An analysis using SEER-Medicare data.

E. Onukwugha

72

Effect of younger age on metastatic rate and prostate cancer specific death for men treated for prostate cancer with radiation therapy: A secondary analysis of RTOG trials.

D. A. Hamstra

84

Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.

K. M. Winkfield

93

Erectile function durability following permanent prostate brachytherapy.

G. S. Merrick

100

Does early PSADT (ePSADT) after radical prostatectomy, calculated using PSA values starting with the first detectable PSA value, correlate with standard PSADT? A report from the SEARCH Database Group.

A. E. Teeter

103

Postoperative radiotherapy for localized prostate cancer: Clinical significance of nadir prostate-specific antigen within 12 months.

K. Ogawa

124

Does PSADT after radical prostatectomy predict overall survival? A report from the SEARCH Database Group.

A. E. Teeter

128

Whole-blood RNA transcript-based prognostic model for predicting survival in men with castration-resistant prostate cancer (CRPC).

W. K. Oh

176

Impact of age at diagnosis on survival in hormone-refractory prostate cancer (HRPC) patients.

M. R. Humphreys

182

Prevalence and severity of pain in men with metastatic prostate cancer.

E. M. Basch

205

Phase I/II open-label study of YM155 plus docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC).

A. W. Tolcher

214




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.